A Double-Blind, Paroxetine- and Placebo-Controlled Study of 50 mg/day and 100 mg/day of EB-1010 among Outpatients with Major Depressive Disorder Who have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
ID Number 10-1681Principal Investigator(s)
Dan V. Iosifescu
Department(s) or Division(s)
The purpose of this study is to test how safe, effective and tolerable an experimental drug called EB-1010 is in patients with major depression. "Experimental" means that the drug has not been approved by the United States Food and Drug Administration (FDA). In this study, EB-1010 will be compared to placebo, a substance that looks like the study drug but has no active ingredients, and to paroxetine, an FDA approved drug to treat patients with major depression. Participants of the study will receive compensation for their participation.
Recruiting Patients: No